Encapsulated polycaprolactone with triazole derivatives and selenium nanoparticles as promising antiproliferative and anticancer agents

Background and purpose: Polycaprolactone nanocapsules incorporated with triazole derivatives in the presence absence of selenium nanoparticles were prepared evaluated as antiproli­ferative anticancer agents. using emulsion technique. Experimental approach: The capsules characterized FT-IR, TEM DLS measurements. synthesized triazo­lopyrimidine derivative encap­sulated polycaprolactone was tested for its vitro efficiency towards human breast cancer cell line (MCF7) murine fibroblast normal (BALB/3T3) comparison to doxorubicin a standard drug. Key results: results indicated that encapsulated polycapro­lactone (SeNPs) triazole-SeNPs most potent samples against (MCF7). On other hand, all compounds showed weak or moderate activities (BALB/3T3). Conclusion: As safety index (SI) higher than 1.0, it expanded way newly express antiproliferative efficacy tumour cells. Hence, these may be considered promising ones. However, they should examined through further in-vivo pharmacokinetic studies.